Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

Pfizer

EMA to review two new Pfizer cancer drugs

August 19, 2011
Sales and Marketing Cancer, Pfizer, bosutinib, crizotinib

The EMA has accepted Pfizer’s regulatory submissions for two of its new cancer compounds. The first is its much-lauded crizotinib, …

News
Roche's Tarceva (erlotinib)

Roche cancer drug Tarceva set for first-line licence

July 25, 2011
Sales and Marketing Cancer, Roche, Tarceva

Roche’s cancer drug Tarceva is on course to win a first-line indication in Europe for the first time after regulatory …

News

Afinitor poised to realise blockbuster ambitions?

July 25, 2011
Sales and Marketing Afinitor, Cancer, Novartis

Novartis’ Afinitor may be set to make good on its blockbuster promise after receiving European backing for its second licence …

News
ASCO 2011

ASCO 2011: news from the front line against cancer

July 18, 2011
Research and Development ASCO, Cancer, oncology

Pharmafocus presents selected highlights from the American Society of Clinical Oncology’s annual meeting in Chicago, beginning with non-small cell lung …

Feature
Amgen

Amgen collaborates on cancer antibody research

July 13, 2011
Research and Development Amgen, Cancer, TGF-beta monoclonal antibody, research and development news

Amgen has teamed up with German biotech Micromet to develop tumour-destroying antibodies in a two-year deal that could net Micromet …

News

BMS licences potential first-in-class cancer biologic

July 7, 2011
Research and Development BMS, Cancer, biologics

Bristol-Myers Squibb has signed a $465 million deal for the rights to a potential first-in-class treatment for cancer. IPH2102 is …

News
rocheroof

Mid-stage trial boost for Roche skin cancer drug vismodegib

June 20, 2011
Research and Development Cancer, Roche, skin cancer, vismodegib

Roche’s novel skin cancer drug vismodegib has met its primary endpoint in a phase II trial. Vismodegib is an investigational, …

News
Roche’s Avastin (bevacizumab)

NHS failed to use extra cancer drug funds

June 17, 2011
Sales and Marketing Cancer, Cancer Drugs Fund, Erbitux, avastin

The million pound fund set up to increase NHS uptake of new cancer drugs was widely underused, with just over …

News

Daiichi Sankyo: Europe poses huge challenge for pharma

June 9, 2011
Research and Development, Sales and Marketing Cancer, Daiichi Sankyo, pricing

Japanese pharma company Daiichi Sankyo is expanding its European operations, creating a new oncology business unit. But outlining its plans …

News

Lansley announces U-turn on cancer networks

May 23, 2011
Cancer, NHS, NHS reforms

Health secretary Andrew Lansley has declared that cancer networks will be maintained, reversing an earlier decision to axe them. Lansley …

News

Blood cancer charity to kick-start clinical trials

May 19, 2011
Research and Development Cancer, blood cancer, clinical trials, leukaemia

A UK blood cancer charity is creating a network of clinical trial centres with backing from the NIHR Clinical Research …

News

GSK withdraws applications for Avodart

March 25, 2011
Research and Development Avodart, Cancer, GSK, bph, prostate cancer

GlaxoSmithKline has withdrawn all regulatory applications for Avodart to prevent prostate cancer after regulators raised doubts about its benefit/risk profile. …

News

Eisai marine sponge derived cancer drug approved in Europe

March 23, 2011
Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate

Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …

News

Dendreon wins green light for Provenge production

March 22, 2011
Manufacturing and Production Cancer, Dendreon, FDA, Provenge, pharma manufacturing, prostate cancer vaccine, sipuleucel-T

US oncology specialist Dendreon has been boosted by the approval of additional production capacity for its therapeutic prostate cancer vaccine …

News
Yondelis - tunicate Ecteinascidia turbin

NICE rejects PharmaMar’s ovarian cancer drug Yondelis

March 14, 2011
Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer

NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026